Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
- PMID: 23337947
- PMCID: PMC3646075
- DOI: 10.1038/mp.2012.194
Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
Abstract
N-methyl-D-aspartate glutamate receptor (NMDA-R) antagonists produce schizophrenia-like positive and negative symptoms in healthy human subjects. Preclinical research suggests that NMDA-R antagonists interfere with the function of gamma-aminobutyric acid (GABA) neurons and alter the brain oscillations. These changes have been hypothesized to contribute to psychosis. In this investigation, we evaluated the hypothesis that the NMDA-R antagonist ketamine produces alterations in cortical functional connectivity during rest that are related to symptoms. We administered ketamine to a primary sample of 22 subjects and to an additional, partially overlapping, sample of 12 subjects. Symptoms before and after the experimental session were rated with the Positive and Negative Syndrome Scale (PANSS). In the primary sample, functional connectivity was measured via functional magnetic resonance imaging almost immediately after infusion began. In the additional sample, this assessment was repeated after 45 min of continuous ketamine infusion. Global, enhanced functional connectivity was observed at both timepoints, and this hyperconnectivity was related to symptoms in a region-specific manner. This study supports the hypothesis that pathological increases in resting brain functional connectivity contribute to the emergence of positive and negative symptoms associated with schizophrenia.
Conflict of interest statement
Conflict of Interest
Dr. Krystal consults for several pharmaceutical and biotechnology companies with compensation less than $10,000 per year. All other authors declare that they have no conflict of interest.
Figures
Similar articles
-
N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia.Biol Psychiatry. 2015 Mar 15;77(6):569-80. doi: 10.1016/j.biopsych.2014.07.022. Epub 2014 Jul 31. Biol Psychiatry. 2015. PMID: 25281999
-
Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.J Psychiatry Neurosci. 2017 Jun;42(4):273-283. doi: 10.1503/jpn.160187. J Psychiatry Neurosci. 2017. PMID: 28556775 Free PMC article. Clinical Trial.
-
Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia.Int J Neuropsychopharmacol. 2015 Apr 19;18(9):pyv040. doi: 10.1093/ijnp/pyv040. Int J Neuropsychopharmacol. 2015. PMID: 25896256 Free PMC article. Clinical Trial.
-
[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].Encephale. 2001 Jan-Feb;27(1):53-9. Encephale. 2001. PMID: 11294039 Review. French.
-
The NMDA antagonist model for schizophrenia: promise and pitfalls.Pharmacopsychiatry. 1998 Jul;31 Suppl 2:104-9. doi: 10.1055/s-2007-979354. Pharmacopsychiatry. 1998. PMID: 9754841 Review.
Cited by
-
Bridging Levels of Understanding in Schizophrenia Through Computational Modeling.Clin Psychol Sci. 2015 May;3(3):433-459. doi: 10.1177/2167702614562041. Clin Psychol Sci. 2015. PMID: 25960938 Free PMC article.
-
Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages.Elife. 2018 Sep 27;7:e37799. doi: 10.7554/eLife.37799. Elife. 2018. PMID: 30260771 Free PMC article.
-
Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia.Mol Psychiatry. 2022 May;27(5):2448-2456. doi: 10.1038/s41380-022-01502-0. Epub 2022 Apr 14. Mol Psychiatry. 2022. PMID: 35422467 Free PMC article. Clinical Trial.
-
Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans.J Neurosci. 2015 Aug 19;35(33):11694-706. doi: 10.1523/JNEUROSCI.0903-15.2015. J Neurosci. 2015. PMID: 26290246 Free PMC article.
-
Divergent pattern of functional connectivity within the dorsal attention network differentiates schizophrenia and bipolar disorder patients.Front Psychiatry. 2024 Sep 19;15:1474313. doi: 10.3389/fpsyt.2024.1474313. eCollection 2024. Front Psychiatry. 2024. PMID: 39364382 Free PMC article.
References
-
- Krystal J, Abi-Dargham A, Laruelle M, Moghaddam B. Pharmacologic model psychoses. In: Charney D, Nestler E, Bunney B, editors. Neurobiology of Mental Illness. Oxford University Press; New York: 1999. pp. 214–224.
-
- Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199–214. - PubMed
-
- Domino E, ChodoffF P, Corsenn G. Pharmacologic Effects of CI-581, a New Dissociative Anesthetic, in Man. Clinical Pharmacology & Therapeutics. 1965;6:279–291. - PubMed
-
- Cohen B, Rosenbaum G, Luby E, Gottlieb J. Comparison of phencyclidine hydrochloride (sernyl) with other drugs: Simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl), lysergic acid diethylamide (lsd-25), and amobarbital (amytal) sodium; ii. symbolic and sequential thinking. Archives of General Psychiatry. 1962;6(5):395–401. - PubMed
-
- Rosenbaum G, Cohen B, Luby E, Gottlieb J, Yelen D. Comparison of sernyl with other drugs: Simulation of schizophrenic performance with sernyl, lsd-25, and amobarbital (amytal) sodium; i. attention, motor function, and proprioception. Archives of General Psychiatry. 1959;1(6):651–656. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
